Company Filing History:
Years Active: 2022
Title: Mohammed Selman: Innovator in Oncolytic RNA Virus Research
Introduction
Mohammed Selman is a prominent inventor based in Ottawa, Canada. He has made significant contributions to the field of cancer research, particularly in the development of methods and compositions that enhance the efficacy of oncolytic RNA viruses. His innovative work aims to improve treatment options for patients suffering from various types of cancer.
Latest Patents
Selman holds a patent for "Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic RNA viruses." This patent outlines methods for enhancing the infection, growth, and spread of oncolytic RNA viruses in cancer cells. It also details how to upregulate cytokine responses and enhance immunotherapeutic activities, ultimately aiming to treat tumors effectively. The methods involve the use of vanadium-containing compounds administered to cancer cells in conjunction with the oncolytic RNA virus.
Career Highlights
Mohammed Selman is affiliated with the Ottawa Hospital Research Institute, where he conducts his research. His work is pivotal in advancing the understanding of oncolytic RNA viruses and their potential in cancer therapy. With a focus on innovative solutions, Selman continues to explore new avenues for enhancing cancer treatment.
Collaborations
Selman collaborates with Jean-Simon Diallo, a fellow researcher in the field. Their partnership is instrumental in driving forward the research on oncolytic RNA viruses and their applications in cancer therapy.
Conclusion
Mohammed Selman's contributions to the field of cancer research through his innovative patent and collaborative efforts highlight his commitment to improving treatment options for patients. His work exemplifies the potential of oncolytic RNA viruses in the fight against cancer.